This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, B. M. Articles by Gerson, S. L. Search for Related Content PubMed PubMed Citation Articles by Davis, B. M. Articles by Gerson, S. L.

Selection for G156A O⁶-Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Protection from Lethality in Mice Treated with O⁶-Benzylguanine and 1,3-Bis(2-chloroethyl)-1-nitrosourea¹

Division of Hematology/Oncology and Molecular Virology Training Program, Case Western Reserve University, University Hospitals of Cleveland Ireland Cancer Center, Cleveland, Ohio 44106

A retroviral gene therapy approach was developed to protect early hematopoietic progenitors from 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a stem cell toxin, and O⁶-benzylguanine (BG), an inhibitor of a key BCNU resistance protein, O⁶-alkylguanine DNA alkyltransferase (AGT). The retroviral vector MFG was used to transfer the G156A MGMT (MGMT) cDNA, encoding a mutant AGT that is resistant to inhibition by BG, into murine bone marrow-derived hematopoietic progenitors. Following transplantation into lethally irradiated mice, the transduced cells were subjected to in vivo BG and BCNU treatment to examine the ability to enrich for transduced cells expressing AGT. Transplantation of MGMT-transduced cells resulted in AGT expression in 30% of bone marrow nucleated cells 13 weeks after transplantation. After one cycle of BG and BCNU, AGT expression was observed in 60% of bone marrow cells, and the percentage of colony-forming units (culture; CFU-C) containing proviral sequence increased from 67 to 100%. CFU-C obtained from BG and BCNU-treated MGMT animals up to 23 weeks after transplantation were more resistant to combination BG and BCNU than CFU-C from mice transplanted with lacZ-transduced cells and treated with BG and BCNU or from mice transplanted with MGMT-transduced cells and left untreated. The degree of drug resistance in MGMT-transduced hematopoietic progenitors to BG and BCNU was much greater than we observed previously with wild-type MGMT gene transfer and treatment with BCNU alone. Furthermore, whereas 21 of 22 mice transplanted with MGMT-transduced cells survived in vivo BG and BCNU administration, only 3 of 13 mice transplanted with lacZ-transduced progenitors survived similar drug treatment. Thus, MGMT-transduced murine bone marrow cells selectively survive in vivo BG and BCNU exposure, resulting in prolonged enrichment for the transduced cells and protection from mortality induced by this drug combination.

¹ This work was supported in part by USPHS Grants P30CA43703, RO1CA63193, RO1ES06288, RO1CA73062, and UO1CA75525.

² To whom requests for reprints should be addressed, at Division of Hematology/Oncology, Case Western Reserve University Hospital, BRB-3W, 10900 Euclid Avenue, Cleveland, OH 44106-4937. Phone: (216) 368-1176; Fax: (216) 368-1166.

Received 4/18/97. Accepted 9/19/97.

This article has been cited by other articles:

				A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128. [Abstract] [Full Text] [PDF]

				M.-R. Lee, S.-H. Kim, H.-J. Cho, K.-Y. Lee, A. R. Moon, H. G. Jeong, J.-S. Lee, J.-W. Hyun, M.-H. Chung, and H. J. You Transcription Factors NF-YA Regulate the Induction of Human OGG1 Following DNA-alkylating Agent Methylmethane Sulfonate (MMS) Treatment J. Biol. Chem., March 12, 2004; 279(11): 9857 - 9866. [Abstract] [Full Text] [PDF]

				E. L. Kreklau, K. E. Pollok, B. J. Bailey, N. Liu, J. R. Hartwell, D. A. Williams, and L. C. Erickson Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea Mol. Cancer Ther., December 1, 2003; 2(12): 1321 - 1329. [Abstract] [Full Text] [PDF]

				C. L. Sweeney, J. L. Frandsen, C. M. Verfaillie, and R. S. McIvor Trimetrexate Inhibits Progression of the Murine 32Dp210 Model of Chronic Myeloid Leukemia in Animals Expressing Drug-resistant Dihydrofolate Reductase Cancer Res., March 15, 2003; 63(6): 1304 - 1310. [Abstract] [Full Text] [PDF]

				S. Kadereit, L. S. Deeds, S. E. Haynesworth, O. N. Koc, M. M. Kozik, E. Szekely, K. Daum-Woods, G. W. Goetchius, P. Fu, L. A. Welniak, et al. Expansion of LTC-ICs and Maintenance of p21 and BCL-2 Expression in Cord Blood CD34+/CD38- Early Progenitors Cultured over Human MSCs as a Feeder Layer Stem Cells, November 1, 2002; 20(6): 573 - 582. [Abstract] [Full Text] [PDF]

				S. L. Gerson Clinical Relevance of MGMT in the Treatment of Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2388 - 2399. [Abstract] [Full Text] [PDF]

				C. A. Warlick, M. D. Diers, J. E. Wagner, and R. S. McIvor In Vivo Selection of Antifolate-Resistant Transgenic Hematopoietic Stem Cells in a Murine Bone Marrow Transplant Model J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 50 - 56. [Abstract] [Full Text] [PDF]

				M. Kobune, Y. Xu, C. Baum, M. R. Kelley, and D. A. Williams Retrovirus-mediated Expression of the Base Excision Repair Proteins, Formamidopyrimidine DNA Glycosylase or Human Oxoguanine DNA Glycosylase, Protects Hematopoietic Cells from N,N',N''-Triethylenethiophosphoramide (thioTEPA)-induced Toxicity in Vitro and in Vivo Cancer Res., July 1, 2001; 61(13): 5116 - 5125. [Abstract] [Full Text] [PDF]

				L. R. Belur, D. Boelk-Galvan, M. D. Diers, R. S. McIvor, and C. L. Zimmerman Methotrexate Accumulates to Similar Levels in Animals Transplanted with Normal versus Drug-resistant Transgenic Marrow Cancer Res., February 1, 2001; 61(4): 1522 - 1526. [Abstract] [Full Text]

				S. Ragg, M. Xu-Welliver, J. Bailey, M. D’Souza, R. Cooper, S. Chandra, R. Seshadri, A. E. Pegg, and D. A. Williams Direct Reversal of DNA Damage by Mutant Methyltransferase Protein Protects Mice against Dose-intensified Chemotherapy and Leads to in Vivo Selection of Hematopoietic Stem Cells Cancer Res., September 1, 2000; 60(18): 5187 - 5195. [Abstract] [Full Text]

				B. M. Davis, O. N. Koc, and S. L. Gerson Limiting numbers of G156A O6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection Blood, May 15, 2000; 95(10): 3078 - 3084. [Abstract] [Full Text] [PDF]

				D. A. Persons and A. W. Nienhuis Gene therapy for the hemoglobin disorders: Past, present, and future PNAS, May 9, 2000; 97(10): 5022 - 5024. [Full Text] [PDF]

				R. Maze, C. Kurpad, A. E. Pegg, L. C. Erickson, and D. A. Williams Retroviral-Mediated Expression of the P140A, but not P140A/G156A, Mutant Form of O6-Methylguanine DNA Methyltransferase Protects Hematopoietic Cells against O6-Benzylguanine Sensitization to Chloroethylnitrosourea Treatment J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1467 - 1474. [Abstract] [Full Text]

				B. J. Glassner, G. Weeda, J. M. Allan, J. L.M. Broekhof, N. H.E. Carls, I. Donker, B. P. Engelward, R. J. Hampson, R. Hersmus, M. J. Hickman, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents Mutagenesis, May 1, 1999; 14(3): 339 - 347. [Abstract] [Full Text] [PDF]

				G. D. LeSage, S. S. Glaser, L. Marucci, A. Benedetti, J. L. Phinizy, R. Rodgers, A. Caligiuri, E. Papa, Z. Tretjak, A.-M. Jezequel, et al. Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1289 - G1301. [Abstract] [Full Text] [PDF]

				M. Xu-Welliver, J. Leitao, S. Kanugula, and A. E. Pegg Alteration of the Conserved Residue Tyrosine-158 to Histidine Renders Human O6-Alkylguanine-DNA Alkyltransferase Insensitive to the Inhibitor O6-Benzylguanine Cancer Res., April 1, 1999; 59(7): 1514 - 1519. [Abstract] [Full Text] [PDF]

				J. S. Reese, B. M. Davis, L. Liu, and S. L. Gerson Simultaneous Protection of G156A Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Sensitization of Tumor Cells Using O6-Benzylguanine and Temozolomide Clin. Cancer Res., January 1, 1999; 5(1): 163 - 169. [Abstract] [Full Text] [PDF]

				B. M. Davis, L. P. Encell, S. P. Zielske, F. C. Christians, L. Liu, S. E. Friebert, L. A. Loeb, and S. L. Gerson Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells PNAS, April 24, 2001; 98(9): 4950 - 4954. [Abstract] [Full Text] [PDF]